|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
5/23/2012 10:53:52 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced that 101 abstracts featuring the Company’s oncology molecules have been accepted at the annual meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, Illinois, June 1-5, 2012. These data include oral presentations on clinical investigations of MLN9708, the first oral proteasome inhibitor being studied in patients with multiple myeloma. Also featured are poster discussions on clinical investigations of TAK-700, a selective 17,20 lyase inhibitor, dosed without steroids in patients with non-metastatic prostate cancer and trials of MLN8237, a selective Aurora A kinase inhibitor, in ovarian and breast cancer patients.
|
|
|
|
|
|
|
|
|
|
|